This website is intended exclusively for healthcare professionals. By clicking Yes, you confirm that you are a registered healthcare professional and understand that the content is not designed for the general public. If you are not a healthcare professional, you must click No and you will be redirected away. Misrepresentation of your status may result in legal consequences.

This page contains promotional content. 

Product resources: Vabysmo▼ (faricimab)

 

Page last updated: 9 September 2025

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to: The Drug Surveillance Centre, Roche Products (Ireland) Limited, telephone: (01) 469 0700, email: ireland.drug_surveillance_centre@roche.com. Or alternatively, report to: HPRA Pharmacovigilance website: www.hpra.ie.

Preparation and injection

 

Administration guide [PDF] (last updated Sept 2025)

Vial handling guide [Video] (last updated April 2025)

Vabysmo (faricimab) PFS Administration Video
(last updated September2025)

Further information

 

Access queries:
Martha Goodwin, martha.goodwin@roche.com

On-licence product information:
Thomas Davis, thomas.davis.td1@roche.com

Tomas Stack, tomas.stack@roche.com

Maitiu O'Nuallain, maitiu.onuallain@roche.com

Please report adverse events to:
The Drug Surveillance Centre

Roche Products (Ireland) Limited

3004 Lake Drive, Citywest, Naas Road, Dublin 24

Tel: +353 (0)1 469 0700

Email: ireland.drug_surveillance_centre@roche.com or

HPRA Pharmacovigilance

Website: hpra.ie

Marketing Authorisation Holder: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany. Vabysmo® is a registered trademark.
You will be re-directed to an external website. Roche accepts no responsibility for the content of other websites.